Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DIsCOvER: Dronabinol in pancreatic cancer
NCT03984214Phase 3Completed
- Sponsor
- Arbeitsgemeinschaft medikamentoese Tumortherapie
- Start
- Dec 2019
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in pancreatic cancer (PC) comparing Dronabinol with Placebo (2 arms). Primary endpoint: Standardized area under the curve of the EORTC QLQ-C30 symptom summary score at 16 weeks. Started Dec 2019; status: completed.
02
Drugs
dronabinol
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT03984214.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03984214.